SynthesisBiomarkers in medicine2025
The role of serum biomarkers as prognostic indicators in pediatric cardiac arrest: a systematic review.
Synthesis in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic inflammatory response drives post-cardiac arrest multi-organ injury via IL-17 signaling in murine and porcine models.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAfter Cardiac Arrest (CA), serum biomarkers (SB) are released to the blood in response to brain damage and, therefore, may be helpful tools to predict neurological outcome. This systematic review aims at assessing the role of SB as neurological outcome indicators after pediatric CA.
methodsA systematic literature search was performed in PubMed, Scopus, WebOfScience and Cochrane Library. All information retrieved from the selected articles was summarized in a data table.
resultsEight studies, including a total of 539 patients, were analyzed. Neurological outcomes were assessed by using the Pediatric Cerebral Performance Category (PCPC) scale in all studies except one. Eleven serum biomarkers were evaluated, with higher concentrations observed in the unfavorable outcome group at various time points. However, only one study defined a specific cutoff value. The biomarkers with the highest predictive accuracy for neurological outcomes appear to be initial levels of IL-17 and CNFT, as well as NSE and S100B.
conclusionFollowing pediatric CA, SB may be helpful indicators of unfavorable neurological outcome, as they seem to appear in higher concentrations in this group. Further research is required to establish specific timepoints and cutoff values and to determine the implication of these findings in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.